Patent: 8,603,521
✉ Email this page to a colleague
Summary for Patent: 8,603,521
Title: | Formulations of histone deacetylase inhibitor and uses thereof |
Abstract: | Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. |
Inventor(s): | Loury; David J. (San Jose, CA), Buggy; Joseph J. (Mountain View, CA), Mody; Tarak D. (Sunnyvale, CA), Verner; Erik J. (Belmont, CA), Purro; Norbert (Los Gatos, CA), Balasubramanian; Sriram (San Carlos, CA) |
Assignee: | Pharmacyclics, Inc. (Sunnyvale, CA) |
Application Number: | 12/761,588 |
Patent Claims: | see list of patent claims |
Details for Patent 8,603,521
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2029-04-17 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2029-04-17 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2029-04-17 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2029-04-17 | |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | 06/01/1989 | ⤷ Try a Trial | 2029-04-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |